Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for treatment of diseases of the central nervous system (CNS). The company markets one product for Epilepsy called Oxtellar XR (TM). Supernus also received approval for an additional product for the treatment of Epilepsy called Trokendi XR. Supernus is also developing psychiatry related drugs for the treatment of ADHD, SPN 810, and SP 812, with plans for significant market potential. For more information, visit the company’s website at www.supernus.com